share_log

Boai NKY Medical Holdings Ltd.'s (SZSE:300109) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Boai NKY Medical Holdings Ltd.'s (SZSE:300109) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

新开源医疗控股有限公司(SZSE:300109)的股票处于上升趋势:强劲的财务状况引导着市场?
Simply Wall St ·  10/04 11:08

Boai NKY Medical Holdings' (SZSE:300109) stock is up by a considerable 26% over the past month. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. In this article, we decided to focus on Boai NKY Medical Holdings' ROE.

新开源医疗控股(SZSE:300109)的股票在过去一个月内大幅上涨了26%。鉴于该公司出色的表现,我们决定更加密切地研究其财务指标,因为公司的财务状况通常决定了市场的长期业绩。在本文中,我们决定重点关注新开源医疗控股的roe。

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.

净资产收益率(ROE)是衡量公司增值和管理投资者资金有效性的测试。换句话说,它是一种盈利能力比率,用于衡量公司股东提供的资金回报率。

How To Calculate Return On Equity?

如何计算股东权益报酬率?

ROE can be calculated by using the formula:

净资产收益率可以使用以下公式进行计算:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

净资产收益率 = 净利润(从持续经营中获得)÷ 股东权益

So, based on the above formula, the ROE for Boai NKY Medical Holdings is:

因此,根据上述公式,新开源医疗控股的roe为:

13% = CN¥440m ÷ CN¥3.4b (Based on the trailing twelve months to June 2024).

13% = 4.4亿人民币 ÷ 340亿人民币(截至2024年6月的过去十二个月)。

The 'return' is the yearly profit. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.13 in profit.

“回报率”是每年利润。这意味着公司为每个CN¥1的股东权益产生了CN¥0.13的利润。

What Has ROE Got To Do With Earnings Growth?

roe与盈利增长有何关系?

So far, we've learned that ROE is a measure of a company's profitability. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

到目前为止,我们已经了解到roe是衡量公司盈利能力的指标。我们现在需要评估公司重新投资或“保留”的利润量,从而给我们提供有关公司增长潜力的想法。其他条件相同的情况下,roe和利润保留率均较高的公司通常是增长率比没有这些特征的公司高的公司。

Boai NKY Medical Holdings' Earnings Growth And 13% ROE

新开源医疗控股的盈利增长和13% roe

To start with, Boai NKY Medical Holdings' ROE looks acceptable. Further, the company's ROE compares quite favorably to the industry average of 6.4%. This probably laid the ground for Boai NKY Medical Holdings' significant 39% net income growth seen over the past five years. We believe that there might also be other aspects that are positively influencing the company's earnings growth. For example, it is possible that the company's management has made some good strategic decisions, or that the company has a low payout ratio.

首先,新开源医疗控股的roe看起来是可以接受的。此外,公司的roe与行业平均水平6.4%相比相当可观。这可能为新开源医疗控股过去五年中显著增长39%的净利润奠定了基础。我们相信,可能还有其他一些积极影响公司盈利增长的方面。例如,公司的管理层可能已经做出了一些良好的战略决策,或者公司的派息率较低。

Next, on comparing with the industry net income growth, we found that Boai NKY Medical Holdings' growth is quite high when compared to the industry average growth of 6.3% in the same period, which is great to see.

接下来,将新开源医疗控股与行业净利润增长进行比较,我们发现新开源医疗控股在同一时期的增长率相当高,远高于行业平均增长率6.3%,这是令人欣慰的。

big
SZSE:300109 Past Earnings Growth October 4th 2024
深圳证券交易所:300109 历史数据 2024年10月4日 盈利增长

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock's future looks promising or ominous. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Boai NKY Medical Holdings is trading on a high P/E or a low P/E, relative to its industry.

估值公司的依据,在很大程度上取决于其盈利增长。投资者需要判断的下一步是,预期的盈利增长是否已经融入股价,或者未融入其中。这样做将有助于他们判断股票的未来是光明还是黑暗。预期盈利增长的一个良好指标是市盈率,它根据企业盈利前景确定市场愿意为股票支付的价格。因此,您可能想要检查新开源医疗控股股票的市盈率是高还是低,相对于其所属行业。

Is Boai NKY Medical Holdings Efficiently Re-investing Its Profits?

新开源医疗控股是否有效地重新投资利润?

Boai NKY Medical Holdings' significant three-year median payout ratio of 57% (where it is retaining only 43% of its income) suggests that the company has been able to achieve a high growth in earnings despite returning most of its income to shareholders.

新开源医疗控股显著的三年中位数分红比率为57%(仅保留收入的43%),表明公司尽管向股东返还大部分收入,仍能实现盈利高增长。

Besides, Boai NKY Medical Holdings has been paying dividends for at least ten years or more. This shows that the company is committed to sharing profits with its shareholders.

此外,新开源医疗控股至少连续十年以上支付股息。这表明公司致力于与股东分享利润。

Conclusion

结论

On the whole, we feel that Boai NKY Medical Holdings' performance has been quite good. Especially the high ROE, Which has contributed to the impressive growth seen in earnings. Despite the company reinvesting only a small portion of its profits, it still has managed to grow its earnings so that is appreciable. Up till now, we've only made a short study of the company's growth data. To gain further insights into Boai NKY Medical Holdings' past profit growth, check out this visualization of past earnings, revenue and cash flows.

总体而言,我们认为新开源医疗控股的表现相当不错。特别是高roe,为收益增长贡献颇多。尽管公司只是重新投资了一小部分利润,但仍设法增长收益,这是令人赞赏的。到目前为止,我们只对公司的增长数据进行了简短的研究。要了解新开源医疗控股过去利润增长情况的更多见解,请查看此可视化的过去收益、营业收入和现金流量。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发